Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held
Telix today announces the official opening of Telix Manufacturing Solutions (TMS) in Yokohama, Japan, the Company’s first cyclotron facility in the Asia Pacific region (APAC).
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
Telix today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab) PET/CT[2] would have undergone a change in clinical management, when compared with baseline standard of care (SOC) imaging. The data will be presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO) being held in Phoenix, AZ, December 2 – 5, 2025.
OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
Telix today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx (89Zr-girentuximab) in metastatic triple negative breast cancer (mTNBC) have been published in the European Journal of Nuclear Medicine and Molecular Imaging.
TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging
Telix today welcomes updated guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM) and The American College of Nuclear Medicine (ACNM) that, for the first time, include the use of Telix’s investigational PET agent, TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), for molecular imaging of renal masses.
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
Telix today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for treating pain associated with bone metastasis.
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
Telix today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise.
TLX400 Therapy Published in Journal of Nuclear Medicine
Telix today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in the Journal of Nuclear Medicine. TLX400 demonstrated clinical antitumor activity with a manageable safety profile in subjects with advanced sarcoma, a patient population with limited treatment options
Telix Announces Record-Breaking Presence at EANM 2025
Telix today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Barcelona from 4 – 8 October 2025.
CMS Grants Transitional Pass-Through Status for Gozellix
Telix today announces that the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging agent for prostate cancer.
IMRA Surgical Announces Collaboration with Telix Pharmaceuticals to Advance Radio-Guided Surgery Education and Training
Telix today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (68Ga) gozetotide injection) to include prostate cancer diagnosis.